Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Lifted by Industrial Alliance Investment Management Inc.

Industrial Alliance Investment Management Inc. raised its stake in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 2.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 24,385 shares of the company’s stock after acquiring an additional 524 shares during the period. Industrial Alliance Investment Management Inc.’s holdings in Moderna were worth $2,884,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of MRNA. Brown Brothers Harriman & Co. raised its stake in Moderna by 3.8% during the 2nd quarter. Brown Brothers Harriman & Co. now owns 1,772 shares of the company’s stock valued at $253,000 after purchasing an additional 65 shares during the period. Kovack Advisors Inc. raised its stake in Moderna by 1.3% during the 3rd quarter. Kovack Advisors Inc. now owns 5,465 shares of the company’s stock valued at $646,000 after purchasing an additional 70 shares during the period. Slow Capital Inc. raised its stake in Moderna by 0.5% during the 3rd quarter. Slow Capital Inc. now owns 14,456 shares of the company’s stock valued at $1,709,000 after purchasing an additional 76 shares during the period. Hexagon Capital Partners LLC raised its stake in Moderna by 31.8% during the 3rd quarter. Hexagon Capital Partners LLC now owns 323 shares of the company’s stock valued at $38,000 after purchasing an additional 78 shares during the period. Finally, Capital Financial Services LLC raised its stake in Moderna by 0.7% during the 3rd quarter. Capital Financial Services LLC now owns 12,469 shares of the company’s stock valued at $1,474,000 after purchasing an additional 85 shares during the period. Institutional investors own 63.11% of the company’s stock.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 245 shares of the company’s stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $163.90, for a total transaction of $40,155.50. Following the completion of the sale, the president now directly owns 1,627,693 shares in the company, valued at $266,778,882.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, President Stephen Hoge sold 245 shares of the company’s stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $163.90, for a total transaction of $40,155.50. Following the completion of the transaction, the president now owns 1,627,693 shares of the company’s stock, valued at $266,778,882.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephane Bancel sold 40,000 shares of the company’s stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $139.20, for a total transaction of $5,568,000.00. Following the transaction, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at approximately $753,342,883.20. The disclosure for this sale can be found here. Insiders sold 506,337 shares of company stock worth $88,716,632 over the last ninety days. Company insiders own 17.30% of the company’s stock.

Moderna Stock Up 1.5 %

MRNA stock opened at $151.78 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.73 and a quick ratio of 2.54. Moderna, Inc. has a 52-week low of $115.03 and a 52-week high of $217.25. The company has a 50-day moving average of $168.13 and a two-hundred day moving average of $160.27. The stock has a market capitalization of $58.64 billion, a price-to-earnings ratio of 7.60 and a beta of 1.70.

Moderna (NASDAQ:MRNA – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The company reported $3.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.66 by ($1.05). Moderna had a net margin of 43.41% and a return on equity of 46.34%. The firm had revenue of $5.08 billion for the quarter, compared to the consensus estimate of $5.02 billion. During the same quarter last year, the company earned $11.29 earnings per share. The firm’s revenue was down 29.5% on a year-over-year basis. As a group, equities research analysts anticipate that Moderna, Inc. will post -2.27 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Royal Bank of Canada assumed coverage on shares of Moderna in a report on Wednesday, March 1st. They set an “outperform” rating and a $200.00 price target on the stock. Morgan Stanley lowered their price target on shares of Moderna from $205.00 to $185.00 in a report on Thursday, February 23rd. Chardan Capital boosted their price target on shares of Moderna from $191.00 to $208.00 and gave the company a “neutral” rating in a report on Wednesday, January 18th. Piper Sandler boosted their price target on shares of Moderna from $214.00 to $217.00 and gave the company an “overweight” rating in a report on Tuesday, December 20th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of Moderna from $225.00 to $200.00 and set a “buy” rating on the stock in a report on Tuesday, February 28th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and an average price target of $180.80.

Moderna Profile

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.